Patient-Reported Outcomes in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) Treated With Belantamab Mafodotin (Belamaf) Versus Pomalidomide Plus Low-Dose Dexamethasone (Pd) in the DREAMM-3 Study
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
multiple myeloma,belantamab mafodotin,relapsed/refractory multiple myeloma,phase III
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要